Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Aegerion Pharmaceuticals, Inc. | earningsrelease110316.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): November 3, 2016
AEGERION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-34921 | 22-2960116 | ||
(State of Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||
One Main Street, Suite 800
Cambridge, MA 02142
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (617) 500-7867
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2016, Aegerion Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2016. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
The following exhibit shall be deemed to be furnished, and not filed:
99.1 Press Release dated November 3, 2016
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 3, 2016
AEGERION PHARMACEUTICALS, INC. | |||
By: | /s/ Gregory D. Perry | ||
Name: | Gregory D. Perry | ||
Title: | Chief Financial and Administrative Officer | ||
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press Related dated November 3, 2016. | |